Singapore Markets close in 6 hrs 42 mins

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
173.49+16.32 (+10.38%)
At close: 4:00PM EDT

172.70 -0.79 (-0.46%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close157.17
Open182.00
Bid172.17 x 900
Ask172.00 x 1800
Day's range165.11 - 189.40
52-week range3.54 - 189.40
Volume17,875,555
Avg. volume9,644,028
Market cap10.182B
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-3.83
Earnings date11 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est142.25
  • Novavax signs COVID-19 vaccine supply deal with India's Serum Institute
    Reuters

    Novavax signs COVID-19 vaccine supply deal with India's Serum Institute

    The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries. The deal was signed on July 30, according to an SEC filing by Novavax. On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.

  • Why Moderna Stock Is Slipping Today
    Motley Fool

    Why Moderna Stock Is Slipping Today

    What happened Shares of Moderna (NASDAQ: MRNA) are slumping today, down 3.9% as of 11:29 a.m. EDT. The biotech reported its second-quarter results before the market opened. However, they don't appear to be the reason behind the decline in Moderna's stock.

  • Why Novavax Stock Is Printing a New All-Time High Today
    Motley Fool

    Why Novavax Stock Is Printing a New All-Time High Today

    Shares of Novavax (NASDAQ: NVAX) jumped by as much as 20.7% in pre-market trading Wednesday morning. Novavax's stock is getting yet another boost from its closely watched COVID-19 vaccine candidate known as NVX-CoV2373. While Novavax is a few months behind the leaders in the race to develop a COVID-19 vaccine, this early stage data suggests that the company might have a best-in-class product.